Insmed rises 5.4% as traders position ahead of near-term catalysts

Insmed Incorporated (INSM) is up 5.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to investors positioning ahead of Insmed’s upcoming first-quarter 2026 earnings report and a slate of May investor-conference appearances, both of which can reset near-term expectations for BRINSUPRI’s launch trajectory and ARIKAYCE performance. Recent bullish analyst actions and updated valuation targets may also be helping sentiment after prior volatility tied to pipeline program changes.

Details:

Insmed has scheduled its first-quarter 2026 financial results release and conference call for May 7, 2026, which can serve as a catalyst for guidance updates and commercial metrics.

The company also announced it will present at May 2026 investor conferences, including a BofA Securities healthcare conference appearance on May 12, 2026.

In recent analyst commentary, at least one firm raised its price target while reiterating a positive rating, pointing to continued focus on commercial execution in respiratory disease.

Company filings highlight BRINSUPRI (brensocatib) as a key growth driver following its U.S. approval and subsequent commercialization build-out, keeping investor attention on launch pace and market access signals.

Sources:

Insmed Investor Relations, Nasdaq, SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$INSM Insider Trading Activity

$INSM insiders have traded $INSM stock on the open market 120 times in the past 6 months. Of those trades, 0 have been purchases and 120 have been sales.

Here’s a breakdown of recent trading of $INSM stock by insiders over the last 6 months:

WILLIAM LEWIS (Chair and CEO) has made 0 purchases and 52 sales selling 130,888 shares for an estimated $21,068,065.
ROGER ADSETT (Chief Operating Officer) has made 0 purchases and 7 sales selling 93,141 shares for an estimated $15,367,891.
LEO LEE has made 0 purchases and 5 sales selling 75,000 shares for an estimated $14,692,249.
MARTINA M.D. FLAMMER (Chief Medical Officer) has made 0 purchases and 29 sales selling 80,487 shares for an estimated $14,591,148.
MICHAEL ALEXANDER SMITH (Chief Legal Officer) has made 0 purchases and 16 sales selling 75,340 shares for an estimated $12,459,520.
ORLOV S NICOLE SCHAEFFER (Chief People Strategy Officer) has made 0 purchases and 4 sales selling 30,000 shares for an estimated $5,820,060.
MELVIN MD SHAROKY sold 20,000 shares for an estimated $4,100,200
ELIZABETH M ANDERSON has made 0 purchases and 2 sales selling 15,000 shares for an estimated $2,981,600.
SARA BONSTEIN (Chief Financial Officer) has made 0 purchases and 4 sales selling 5,390 shares for an estimated $925,675.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

EARLY ACCESS

Receive INSM Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$INSM Hedge Fund Activity

We have seen 376 institutional investors add shares of $INSM stock to their portfolio, and 304 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

PRICE T ROWE ASSOCIATES INC /MD/ removed 2,892,000 shares (-41.7%) from their portfolio in Q4 2025, for an estimated $503,323,680
BLACKROCK, INC. added 2,700,148 shares (+21.8%) to their portfolio in Q4 2025, for an estimated $469,933,757
CAPITAL INTERNATIONAL INVESTORS removed 2,402,182 shares (-31.8%) from their portfolio in Q4 2025, for an estimated $418,075,755
RTW INVESTMENTS, LP added 1,758,321 shares (+57.0%) to their portfolio in Q4 2025, for an estimated $306,018,186
QUBE RESEARCH & TECHNOLOGIES LTD removed 1,544,315 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $268,772,582
D. E. SHAW & CO., INC. removed 1,306,469 shares (-23.1%) from their portfolio in Q4 2025, for an estimated $227,377,864
STATE STREET CORP added 1,217,390 shares (+30.6%) to their portfolio in Q4 2025, for an estimated $211,874,555

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

$INSM Analyst Ratings

Wall Street analysts have issued reports on $INSM in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 02/23/2026
UBS issued a "Buy" rating on 01/06/2026
TD Cowen issued a "Buy" rating on 12/18/2025
Goldman Sachs issued a "Buy" rating on 12/18/2025
Wells Fargo issued a "Overweight" rating on 12/16/2025
Mizuho issued a "Outperform" rating on 12/01/2025

To track analyst ratings and price targets for $INSM, check out Quiver Quantitative's $INSM forecast page.

$INSM Price Targets

Multiple analysts have issued price targets for $INSM recently. We have seen 16 analysts offer price targets for $INSM in the last 6 months, with a median target of $215.5.

Here are some recent targets:

Adam Walsh from Roth Capital set a target price of $212.0 on 04/17/2026
Leonid Timashev from RBC Capital set a target price of $216.0 on 04/14/2026
Eliana Merle from Barclays set a target price of $237.0 on 04/01/2026
Matthew Harrison from Morgan Stanley set a target price of $212.0 on 03/30/2026
Andrew S. Fein from HC Wainwright & Co. set a target price of $245.0 on 03/26/2026
Graig Suvannavejh from Mizuho set a target price of $206.0 on 03/25/2026
Jason Zemansky from B of A Securities set a target price of $213.0 on 03/24/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.